Alnylam's Heart Drug Just Hit a Wall Street Trust Crisis
Alnylam's heart drug vutrisiran has strong clinical data, but a competitor's trial failure, a revenue guidance cut, and a 30% stock drop have created a perfect storm of skepticism. Now the biggest cardiology meeting of the year could decide whether Wall Street buys back in.
The Stock Dropped 30%. Then the Cardiologists Showed Up.
Imagine spending years building a rocket, launching it successfully, and then watching the crowd argue about whether the sky is even real. That's roughly where Alnylam Pharmaceuticals finds itself heading into the European Society of Cardiology (ESC) Congress 2026 in Munich.
The company's flagship heart drug, vutrisiran (brand name AMVUTTRA), is an RNA interference therapy designed to silence the gene behind a deadly heart condition. The clinical data look strong. The science is real. But Wall Street has turned skeptical, and now the biggest cardiology meeting of the year is putting Alnylam's entire cardiovascular franchise under a microscope.
Alnylam's stock has fallen roughly 30% in the past month. That kind of drop doesn't happen because of one bad headline. It happens when confidence cracks.
A Quick Decoder Ring for the Science
Let's back up. Vutrisiran treats a condition called ATTR cardiomyopathy (ATTR-CM), where a misfolded protein called transthyretin builds up in the heart like plaque in old pipes. Over time, the heart stiffens and fails. It's a disease that was barely diagnosed a decade ago, but better testing has revealed it's far more common than anyone thought.
Vutrisiran works using RNA interference, or RNAi: a Nobel Prize-winning technology that essentially shoots the messenger. Your liver makes the troublesome protein by reading genetic instructions carried by messenger RNA. Vutrisiran intercepts those instructions and shreds them before the protein ever gets made. Think of it as deleting a bad recipe from the cookbook before the chef even starts cooking.
The drug is dosed as a subcutaneous injection every three months, which is a huge convenience win in a field where older therapies required IV infusions.
The Data That Should Be a Victory Lap
Alnylam's pivotal trial, HELIOS-B, has produced numbers that most biotech companies would frame and hang on the wall. Vutrisiran cut the risk of death or cardiovascular events by and . The mortality reduction alone was striking: , rising to in the monotherapy group at the prespecified Month 42 analysis.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
37% in the overall population
42% in patients who weren't on another ATTR therapy
36% overall
35%
Those aren't marginal improvements. In cardiology, where shaving a few percentage points off mortality can earn blockbuster status, those are the kinds of results that change treatment guidelines.
The safety profile has been equally cooperative. Adverse event rates were similar between vutrisiran and placebo. Discontinuation rates were low in both groups. A pooled safety analysis covering more than 25,000 patient-years of exposure across vutrisiran and the older RNAi drug patisiran found no clinically meaningful vitamin A deficiency (a theoretical concern with this class of drugs) and low rates of eye-related side effects.
At ESC 2026, Alnylam is presenting even more analyses: fewer adverse events versus placebo, benefits on "healthy aging" measures, and outcomes broken down by sex and baseline therapy use. On paper, this is a company playing offense.
So Why Is Everyone Nervous?
Two words: collateral damage.
A competing drug in the ATTR-CM space, eplontersen, recently failed its own late-stage heart trial (called CARDIO-TTRansform). That failure sent shockwaves through the entire field. Cardiologists and investors started asking uncomfortable questions: if one protein-silencing drug flopped in ATTR-CM, what does that mean for the others?
The analogy is a bit like one airline having a crash and passengers suddenly refusing to fly on any airline. Alnylam's vutrisiran works by a similar (though not identical) mechanism, so the guilt-by-association effect has been real.
Making matters worse, Alnylam's Q2 2026 earnings report disappointed investors. The company cut its full-year revenue guidance, raising concerns about the pace of vutrisiran's commercial launch in ATTR-CM. Wall Street had been pricing in a fast ramp. The revised numbers suggested a slower climb.
The combination was toxic for the stock. One analyst consensus still rates Alnylam a Buy, but the mood has clearly shifted. Investors are demanding proof that vutrisiran's clinical wins can translate into commercial ones.
A Bigger Battlefield Than It Used to Be
The ATTR-CM market isn't the sleepy niche it was five years ago. It's now a multi-billion-dollar arena with real competition.
Tafamidis (sold by Pfizer) was the first approved therapy and remains the benchmark. It works differently; instead of destroying the misfolded protein, it stabilizes it so it doesn't fall apart and clump in the heart. Annual cost: roughly $268,000. A newer stabilizer, acoramidis, has also entered the market.
Vutrisiran and other RNAi therapies sit at a higher price point, which creates its own challenges. Payers are watching closely. Cost-effectiveness analyses suggest significant price reductions may be needed for broad coverage.
The market is evolving toward a multi-mechanism approach: stabilizers to hold the protein together, silencers (like vutrisiran) to stop production, and eventually "depleters" or gene-editing therapies to clear existing deposits. Alnylam needs to prove that its silencer deserves a central role in that ecosystem, not just a supporting one.
What ESC Could Change
Alnylam is bringing more than just vutrisiran to Munich. The company is also presenting data on zilebesiran, an RNAi therapy for uncontrolled hypertension (high blood pressure). A subgroup analysis from the Phase 2 KARDIA-3 trial will show how zilebesiran performed in patients already on a diuretic, while a larger Phase 3 outcomes trial called ZENITH continues to run.
Hypertension is a massive market, and an RNAi-based treatment that works for months from a single injection could be transformative. But it's also earlier-stage and won't move the stock the way a vutrisiran narrative shift would.
The real question at ESC is whether Alnylam's additional HELIOS-B analyses can rebuild confidence. Can they show that vutrisiran's benefits hold up across the subgroups that matter most to prescribers? Can the safety data silence (pun intended) the anxiety caused by eplontersen's failure?
The Bottom Line
Alnylam is in a strange position: strong data, weak sentiment. The clinical story keeps getting better, but the commercial and competitive narrative has introduced enough doubt to knock a third off the stock price.
ESC 2026 won't be a single make-or-break moment. But it's the highest-profile stage Alnylam will get this year to remind the cardiology world (and Wall Street) what its data actually show. Sometimes the best defense isn't a new drug; it's making sure people actually read the results you already have.
4 min read
The $795M Bet on a Brain Channel That Already Failed Once
SK Biopharmaceuticals just paid $795 million for a drug that targets the same brain channel class that flopped a decade ago. The early data on opakalim suggests the second-generation version might actually be worth it.
